Pfizer, BioNTech win FDA approval for XFG-adapted COVID-19 vaccine in high-risk US adults
PFE•Shipments begin immediately
The companies said shipments start immediately, supporting near-term seasonal demand in the U.S. market.
FDA clears XFG-adapted COMIRNATY for 2026-2027 season
Pfizer and BioNTech said the U.S. Food and Drug Administration has cleared Pfizer’s supplemental filing for an XFG-adapted COMIRNATY COVID-19 shot for the 2026-2027 season.
The authorization covers adults 65 and older, plus people ages 5 to 64 with at least one high-risk underlying condition.
